Document is current

Any future updates will be listed below

Retraction Note: Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin

Crossref DOI link: https://doi.org/10.1038/s41598-025-31415-1

Published Online: 2025-12-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark